259 related articles for article (PubMed ID: 10572421)
1. [DDS preparations of drugs for inflammatory bowel disease].
Takada K
Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
3. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
6. Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery.
Zambito Y; Di Colo G
J Pharm Pharm Sci; 2003; 6(2):274-81. PubMed ID: 12935439
[TBL] [Abstract][Full Text] [Related]
7. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Takaya T; Sawada K; Suzuki H; Funaoka A; Matsuda K; Takada K
J Drug Target; 1997; 4(5):271-6. PubMed ID: 9169983
[TBL] [Abstract][Full Text] [Related]
8. Carboxymethyl starch and lecithin complex as matrix for targeted drug delivery: I. Monolithic mesalamine forms for colon delivery.
Mihaela Friciu M; Canh Le T; Ispas-Szabo P; Mateescu MA
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):521-30. PubMed ID: 23562535
[TBL] [Abstract][Full Text] [Related]
9. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
Klotz U
Med Klin (Munich); 1999 Feb; 94 Suppl 1():16-22. PubMed ID: 10194943
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
Dubey R; Dubey R; Omrey P; Vyas SP; Jain SK
J Drug Target; 2010 Sep; 18(8):589-601. PubMed ID: 20088681
[TBL] [Abstract][Full Text] [Related]
12. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract.
Watts P; Smith A
Expert Opin Drug Deliv; 2005 Jan; 2(1):159-67. PubMed ID: 16296742
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of DDS, steroid therapy and NSAIDs].
Hoshi K
Nihon Rinsho; 1989 Jun; 47(6):1302-7. PubMed ID: 2769991
[No Abstract] [Full Text] [Related]
14. [Study on in vitro release empirical method and the release mechanism of budesonide colonic localization tablet].
Liu H; Pan WS; Nie SF; Yang XG; Yan TX
Yao Xue Xue Bao; 2008 Nov; 43(11):1147-51. PubMed ID: 19239036
[TBL] [Abstract][Full Text] [Related]
15. [Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease].
Stange EF
Med Klin (Munich); 1999 Feb; 94 Suppl 1():39-41. PubMed ID: 10194947
[TBL] [Abstract][Full Text] [Related]
16. [Galenic aspects and therapy of chronic inflammatory bowel diseases. Introduction].
Schölmerich J
Med Klin (Munich); 1999 Feb; 94 Suppl 1():3. PubMed ID: 10194939
[No Abstract] [Full Text] [Related]
17. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
Gross V
Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
[TBL] [Abstract][Full Text] [Related]
18. [Ulcerative colitis--colon delivery of 5-aminosalicylic acid].
Muraoka M; Kimura G; Zhaopeng H; Takada K
Nihon Rinsho; 1998 Mar; 56(3):788-94. PubMed ID: 9549374
[TBL] [Abstract][Full Text] [Related]
19. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Nugent SG; Kumar D; Rampton DS; Evans DF
Gut; 2001 Apr; 48(4):571-7. PubMed ID: 11247905
[TBL] [Abstract][Full Text] [Related]
20. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
